Piramal Pharma drops 5% after listing at Rs 201.80; Motilal sees Rs 210 as fair value

Piramal Pharma has a differentiated business model, comprising contract development and manufacturing (59% of sales in FY22), complex hospital generics (30% of sales), and India Consumer products (11% of sales)

Related Keywords

India ,Piramal Pharma ,Motilal Oswal ,Shareholders Of Piramal Enterprises ,Piramal Enterprises ,India Consumer ,Pad Pro ,Piramal Pharma Listing ,Piramal Pharma Share Price ,Iramal Pharma Stock Price ,Iramal Pharma Debut ,